| Literature DB >> 32175710 |
Annika B Wilder-Smith1, Kaveri Qureshi2.
Abstract
BACKGROUND AND OBJECTIVES: Europe has experienced a major resurgence of measles in recent years, despite the availability and free access to a safe, effective, and affordable vaccination measles, mumps and rubella vaccine (MMR). The main driver for this is suboptimal vaccine coverage. The three objectives of this study are to synthesize and critically assess parental attitudes and beliefs toward MMR uptake, to develop strategies and policy recommendations to effectively improve MMR vaccine uptake accordingly, and ultimately to identify areas for further research.Entities:
Keywords: Vaccine confidence; Wakefield; measles; vaccine hesitancy; vaccine refusal
Mesh:
Substances:
Year: 2020 PMID: 32175710 PMCID: PMC7310814 DOI: 10.2991/jegh.k.191117.001
Source DB: PubMed Journal: J Epidemiol Glob Health ISSN: 2210-6006
Figure 1Search string used for Medline database.
Exclusion and inclusion criteria
| Study design | Title or abstract must mention measles or measles vaccination. | Studies published before 2011. |
| Title or abstract must mention ‘vaccine uptake’, ‘attitudes’, ‘acceptance’, ‘hesitancy’, or ‘refusal’. | Studies not in English. | |
| Primary data. | Secondary data. | |
| Focus groups, in-depth interviews, questionnaires, and surveys. | Purely quantitative data. | |
| Study population | Parental population group. | Study population of only children, adolescents, healthcare workers, or students. |
| Studies conducted only in Europe. | Studies conducted outside Europe. | |
| Research topic | Studies focusing on attitudes or beliefs about measles vaccine. | Studies focusing primarily on effectiveness of interventions, epidemiological mapping, or serological research. |
A summary of study characteristics
| 1 | Brown, Fraser, Ramsay et al. [ | 2011 | UK | To explore attitudes and predictors of MMR catch-up vaccine uptake. | Self-administered questionnaire | 365 UK parents whose children aged 5–18 years had received <2 MMR doses before 2008. | Quantitative analysis | 7/10 |
| 2 | Brown, Long, Ramsay et al. [ | 2012 | UK | To explore parents’ MMR decision making since 2004. | Semi-structured interviews | 24 mothers planning to accept, postpone or decline the first MMR dose for their 11–36 month old children. | Grounded theory approach | 8/10 |
| 3 | Byström, Lindstrand, Likhite et al. [ | 2014 | Sweden | To explore facilitators and barriers to MMR vaccination among parents living in anthroposophical communities in Sweden. | In-depth interviews | 20 parents in an anthroposophical community. | Qualitative content analysis | 7/10 |
| 4 | Camerini, Diviani, Fadda et al. [ | 2019 | Switzerland | To identify predictors of parents’ intention to adhere to official MMR vaccination recommendations. | Self-administered questionnaire | 554 parents of middle school students aged 13 to 15. | Quantitative analysis | 8/10 |
| 5 | Fadda, Depping and Schulz [ | 2015 | Switzerland | To understand what drives parents’ decision to vaccinate against measles, with a focus on vaccination literacy and psychological empowerment. | Semi-structured interviews | 20 parents, of at least one child under 1 year, of permanent residence in Ticino. | Inductive thematic analysis | 8/10 |
| 6 | Fadda, Galimberti, Carraro et al. [ | 2016 | Italy | To gain insights from parents residing in a low MMR uptake area on what constitutes feelings of empowerment in the decision they have to make on their child’s MMR vaccination. | Focus group interviews | 24 mothers and 4 fathers of children for whom the MMR vaccination decision was still pending. Parents residing in Italy, of at least one child ages <1 year. | Inductive thematic analysis | 7/10 |
| 7 | Giambi, Fabiani, D’Ancona et al. [ | 2018 | Italy | To estimate vaccine hesitancy and investigate its determinants among parents of children aged 16–36 months. | Questionnaire | Parents of children aged 16–36 months. 3130 questionnaires used in analysis. | Multivariable logistic regression | 9/10 |
| 8 | Gross, Hartmann, Zemp et al. [ | 2015 | Switzerland | To investigate how Swiss parents use natural development of the child to explain their critical attitudes towards immunisation against measles and other childhood diseases. | Semi-structured interviews | 32 interviews with parents of children between 0 and 16 years who decided not to fully immunise their children. | Qualitative content analysis | 9/10 |
| 9 | Jama, Ali, Lindstrand et al. [ | 2018 | Sweden | To explore factors influencing the decision of Somali parents living in 2 districts of Stockholm, Sweden, on whether to vaccinate their children with MMR. | In-depth interviews | 13 mothers of at least one child aged 18 months to 5 years. | Qualitative content analysis | 8/10 |
| 10 | Johnson and Capdevila [ | 2014 | UK | To explore the ways mothers make sense of and work with varying advice and information within their contexts and circumstances, in relation to MMR and vaccinations. | Focus group interviews | 5 mothers of preschool children between ages 12 and 18 months. | Thematic analysis | 6/10 |
| 11 | Kennedy, Brunton and Hogg [ | 2013 | UK | To explore vaccination views in Scotland amongst parents, teenage girls and health professionals across 3 controversial vaccines and consider contextual influences on decision-making. | Semi-structured interviews and focus group discussions. | 51 health professionals, 15 parents and 8 teenage girls aged 12–15 years. | Iterative thematic analysis | 8/10 |
| 12 | Klomp, van Lier and Ruijs [ | 2014 | The Netherlands | To get an insight into the attitudes towards childhood vaccination of parents with children attending anthroposophical schools. | Questionnaire | 458 parents of children aged 4–18 years at anthroposophical schools in Gelderland. | Quantitative analysis | 6/10 |
| 13 | Kriwy [ | 2012 | Germany | To investigate parental decisions to vaccinate their children against MMR. | Database analysis and surveys | Database: 9270 children Survey: 464 parents and 136 physicians. | Quantitative analysis | 7/10 |
| 14 | McHale, Keenan and Ghebrehewet [ | 2015 | UK | To identify factors that continue to affect MMR uptake rates and consider key issues related to parents or carers of confirmed measles cases. | Semi-structured interviews | Parents or carers of 47 unvaccinated measles cases aged between 13 months and 9 years. | Thematic analysis | 9/10 |
| 15 | Newton and Smith [ | 2017 | UK | To explore Gypsy, Roma and Traveller parents’ beliefs about childhood immunisation, the risks of immunisation and nonimmunisation, obstacles to and facilitators of immunisation and views on increasing immunisation levels. | Focus group interviews | 16 Gypsy and Traveller women with pre-school aged children. | Thematic analysis | 8/10 |
| 16 | Restivo, Napoli, Marsala et al. [ | 2014 | Italy | To evaluate the refusal level of first MMR dose, and investigate sociodemographic characteristics associated with refused vaccination and reasons reported by parents for their child’s immunisation status. | Questionnaire | 443 parents who accepted/refused first dose of MMR vaccination for children in 13–20th month. | Quantitative analysis | 7/10 |
| 17 | Rey, Fressard, Cortaredona et al. [ | 2018 | France | To estimate the prevalence and socio-demographic correlates of vaccine hesitancy in sub-groups of the French population. To investigate the association of vaccine hesitancy with both vaccine uptake and perceived risk-benefit balance for four vaccines. | Telephone survey | 3938 parents between 15–75 years: | Quantitative analysis | 8/10 |
| 18 | Smith and Newton [ | 2016 | UK | To explore the issues Gypsy, Roma and Traveller (GRT) parents consider when making vaccination decisions in the context of wider social, ideological, material and practical considerations. | Focus group interviews | 5 focus groups of 16 GRT women, who had 35 children between them. 13 were not immunised. | Thematic analysis | 8/10 |
| 19 | Walsh, Thomas, Mason et al. [ | 2014 | UK | To investigate parents’ decision on whether to accept MMR. | Self-administered questionnaire | 66 parents/guardians of children aged 2 who have not received MMR. | Quantitative analysis | 8/10 |
| 20 | Weiss, Schröpfer and Merten [ | 2016 | Switzerland | To investigate how patterns of parental attitudes are linked to the decision-making process for or against MMR vaccination. | Questionnaire | 189 parents of children <36 months. | Quantitative analysis | 9/10 |
Figure 2PRISMA flow diagram of the complete search process.
Themes that emerged promoting MMR vaccine uptake
| Vaccine factors | Provide herd immunity | 1–5, 7, 10 |
| Protect the child | 3, 4, 7, 19, 20 | |
| Belief in vaccine efficacy | 4, 15, 18, 19 | |
| Belief in vaccine safety | 1, 6, 19 | |
| Benefits outweigh risks | 19 | |
| Can easily treat complications of vaccine | 20 | |
| Child mixing with unimmunized people | 2 | |
| Measles factors | Concern about severity of measles | 1, 2, 18, 19, 20 |
| Concern about susceptibility to measles | 4, 15 | |
| Lack of time/ability/competence to deal with measles | 3 | |
| Trust factors | Trust in healthcare workers, experts, or government | 2, 3, 5, 6, 7, 9, 19, 20 |
| Trust in God | 9 | |
| Social factors | Social desirability | 1, 2, 4, 10 |
| Responsibility over child | 10, 11, 19 | |
| Decision to vaccinate is intuitive | 3, 5, 10 | |
| Follow social norm | 5 | |
| Guilt for non-vaccination | 2 | |
| Practical factors | Follow recommendations | 2–4, 7, 10 |
| Little time to make informed decision | 10 | |
| Knowledge factors | Influence from peers/family | 1, 9 |
| Satisfied with information | 1 |
Themes that emerged promoting MMR vaccine hesitancy or refusal
| Vaccine factors | Fear of vaccine side effects | 2–9, 13, 15, 17, 19, 20 |
| Doubts of vaccine safety | 2, 3, 6, 7, 9–12, 14 | |
| High risk compared to benefit from vaccine | 7–9, 12, 13, 15, 17, 18 | |
| Experience (self/peers) of vaccine side effects | 2, 4, 5, 9, 11, 14, 18 | |
| Vaccination given too young | 2, 3, 7–9, 15, 18 | |
| Fear of combined vaccines | 7, 11, 15, 18, 19 | |
| Immune overloading | 2, 7, 8, 12 | |
| Doubts of vaccine efficacy | 2, 8, 12, 17 | |
| Fear of vaccine constituents | 2, 7, 10, 14 | |
| Intrusion/invasive procedure | 8, 15, 18, 20 | |
| Doubts of necessity of vaccine | 7, 12 | |
| Family history of autism | 19 | |
| Measles factors | Lack of severity of measles | 4, 5, 7–9, 13–15, 18, 20 |
| Perceived low susceptibility to measles | 4, 5, 8, 9, 15 | |
| Measles helps child development | 3, 8, 19 | |
| Competence to cope with measles | 3 | |
| Trust factors | Mistrust in healthcare workers/experts/government | 2, 3, 5, 6, 10, 11, 18, 19 |
| Bad experience/relationship/communication with healthcare workers | 9, 10, 13, 14, 18 | |
| Fear of commercial motivation | 2, 7, 20 | |
| Social factors | Natural immunity preferred | 2, 3, 5, 8, 12, 19, 20 |
| Alternative medicine preferred | 3, 12–14 | |
| Right to autonomous decision | 3, 5, 16, 18 | |
| Healthy lifestyle measures are sufficient to treat/prevent | 2, 5, 7, 8 | |
| Decision requires more time | 3, 6 | |
| Disease is a natural part of life | 3 | |
| Fear of judgement from peers | 9 | |
| Practical factors | Contradictions to vaccination | 7, 14–16, 18 |
| Access to clinics | 15, 16, 18 | |
| Temporary residence | 14, 15, 18 | |
| Forgetfulness | 7, 14, 15 | |
| Competing priorities | 15, 18 | |
| Cost of individual vaccine | 15, 18 | |
| Did not receive timely vaccination invitation | 1, 7 | |
| Vaccine not offered | 14 | |
| Knowledge factors | Insufficient information | 2, 7, 9, 10, 13, 14, 16, 18 |
| Misinformation online/media | 11, 14, 16, 18, 19 | |
| Lack competence to make decision | 5, 6 | |
| Discordant information | 7, 10 | |
| Lay knowledge from family/peers | 15, 20 | |
| Advised against/cautioned by healthcare provider | 7, 11 |
| TITLE | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| INTRODUCTION | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 4 |
| METHODS | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 5 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 4/5 Figure 2 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4/5 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | Figure 1 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 4/5 Figure 1/2 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 5 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 5 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 5 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | 5 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 5 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | n/a |
| RESULTS | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | Figure 2 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | Table 2 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see Item 12). | Table 2 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | Table 2 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | n/a |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | Table 2 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | n/a |
| DISCUSSION | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 6–10 Table 3/4 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 13/14 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 13–15 |
| FUNDING | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 15 |